

ForPatients

by Roche

Breast Cancer HER2-Positive Breast Cancer

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

Trial Status
Recruiting

Trial Runs In
1 Countries

Trial Identifier
NCT05945927 ML44675

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study is a post-marketing, observational, multicenter, prospective study. It will investigate the the safety and effectiveness of T-DM1 in the Chinese population in real-world clinical practice.

Hoffmann-La Roche
Sponsor

NCT05945927 ML44675
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
>=18 Years

Healthy Volunteers
No
